Skip to main content
. 2020 May 1;11:2163. doi: 10.1038/s41467-020-15729-4

Fig. 7. CD4+ and CD8+ T cells customized with AsNRs can target and inhibit solid tumors.

Fig. 7

a Schematic showing the experimental strategy for e and f. CD19+ tumor cells were implanted on the right leg and CD19− tumor cells were implanted on the contralateral leg. The engineered T cells were i.v. injected at D5 and CD3+ T cells were injected into tumors. b Immunotherapy strategy for treating tumors showing that the engineered T cells secreted BFP reporter and blinatumomab (α-CD19/CD3 BiTE) after they sensed the endothelium of the sprouting vessels, and CD3+ T cells were retargeted to CD19+ tumor cells. c Quantitative analysis results showing the mRNA level of blinatumomab when engineered cells were in direct contact with HUVECs. d Analysis of the BFP+ cells by flow cytometry after they sensed the HUVECs in vitro. e Analysis of the BFP+ cells by flow cytometry showing that the T cells engineered with the BiTE system were activated after sensing tumor endothelium. f Tumor growth curves showing that the volume of the tumors was significantly reduced whether or not CD3+ T cells were injected compared with volume of CD19 tumors, but the reduction was more significant after the injection of the CD3+ cells. Error bars: SEM. Significance: ***p < 0.001, **p < 0.01, *p < 0.05 (n = 3 in c–e, n = 5 mice for each group in f).